Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
Parabilis Medicines will present updated Phase 1/2 data for zolucatetide in desmoid tumors in an oral session at ESMO Congress 2026 on October 24, in Madrid. The data, with a June 22, 2026 cut-off, will cover both dose escalation and dose optimization arms, which are designed to select the dose and schedule for a planned registrational Phase 3 trial. Zolucatetide holds FDA Fast Track and Orphan Drug designations for desmoid tumors, an indication with an estimated 30,000 U.S. patients and no approved therapy directly targeting Wnt/β-catenin biology.
Key figures
- Drug Name
- zolucatetide
- Phase Of Trial
- Phase 1/2
- Abstract number
- 3715O
- Us patients actively managed
- 11000
- Us desmoid tumor patients estimated
- 30000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.